Hello, and welcome to the Hexcel fourth-quarter and full-year 2024 earnings call. (Operator Instructions) I would now like to turn the conference over to Patrick Winterlich, Chief Financial Officer.
The FDA recently granted marketing authorization for the TriVerity Test System — a new molecular diagnostic test developed by Inflammatix. This first-of-its-kind test provides a comprehensive ...
The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...
Hexcel Corporation reported its fourth-quarter 2024 earnings, showcasing a strong performance with an adjusted earnings per share (EPS) of $0.52, surpassing the forecasted $0.50. The company's revenue ...